nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC22A5—Dactinomycin—muscle cancer	0.642	0.825	CbGbCtD
Ceftazidime—SLC22A6—Methotrexate—muscle cancer	0.136	0.175	CbGbCtD
Ceftazidime—Nephropathy—Etoposide—muscle cancer	0.00519	0.0234	CcSEcCtD
Ceftazidime—Myoclonus—Vincristine—muscle cancer	0.00507	0.0229	CcSEcCtD
Ceftazidime—Reaction gastrointestinal—Methotrexate—muscle cancer	0.00443	0.02	CcSEcCtD
Ceftazidime—Nephropathy toxic—Etoposide—muscle cancer	0.0043	0.0194	CcSEcCtD
Ceftazidime—Aplastic anaemia—Dactinomycin—muscle cancer	0.0032	0.0145	CcSEcCtD
Ceftazidime—Prothrombin level increased—Doxorubicin—muscle cancer	0.00312	0.0141	CcSEcCtD
Ceftazidime—Nephropathy—Methotrexate—muscle cancer	0.00311	0.014	CcSEcCtD
Ceftazidime—Phlebitis—Dactinomycin—muscle cancer	0.00288	0.013	CcSEcCtD
Ceftazidime—Coma—Vincristine—muscle cancer	0.00279	0.0126	CcSEcCtD
Ceftazidime—Inflammation—Etoposide—muscle cancer	0.00255	0.0115	CcSEcCtD
Ceftazidime—Lethargy—Dactinomycin—muscle cancer	0.00253	0.0114	CcSEcCtD
Ceftazidime—Candida infection—Etoposide—muscle cancer	0.00236	0.0106	CcSEcCtD
Ceftazidime—Skin exfoliation—Etoposide—muscle cancer	0.00236	0.0106	CcSEcCtD
Ceftazidime—Local reaction—Doxorubicin—muscle cancer	0.00231	0.0104	CcSEcCtD
Ceftazidime—Encephalopathy—Methotrexate—muscle cancer	0.00231	0.0104	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.00223	0.0101	CcSEcCtD
Ceftazidime—Phlebitis—Etoposide—muscle cancer	0.00208	0.00939	CcSEcCtD
Ceftazidime—Thrombocytosis—Doxorubicin—muscle cancer	0.00206	0.00929	CcSEcCtD
Ceftazidime—Pancytopenia—Dactinomycin—muscle cancer	0.00203	0.00917	CcSEcCtD
Ceftazidime—Oral candidiasis—Doxorubicin—muscle cancer	0.00202	0.0091	CcSEcCtD
Ceftazidime—Neutropenia—Dactinomycin—muscle cancer	0.002	0.00903	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00189	0.00854	CcSEcCtD
Ceftazidime—Pancytopenia—Vincristine—muscle cancer	0.00182	0.0082	CcSEcCtD
Ceftazidime—Neutropenia—Vincristine—muscle cancer	0.00179	0.00807	CcSEcCtD
Ceftazidime—Agranulocytosis—Dactinomycin—muscle cancer	0.00178	0.00804	CcSEcCtD
Ceftazidime—Dermatitis atopic—Doxorubicin—muscle cancer	0.00173	0.00781	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.00163	0.00734	CcSEcCtD
Ceftazidime—Erythema multiforme—Dactinomycin—muscle cancer	0.00162	0.00731	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00161	0.00728	CcSEcCtD
Ceftazidime—Flushing—Dactinomycin—muscle cancer	0.00159	0.00718	CcSEcCtD
Ceftazidime—Injection site pain—Doxorubicin—muscle cancer	0.00157	0.00708	CcSEcCtD
Ceftazidime—Inflammation—Methotrexate—muscle cancer	0.00153	0.00688	CcSEcCtD
Ceftazidime—Bronchospasm—Etoposide—muscle cancer	0.00152	0.00688	CcSEcCtD
Ceftazidime—Hallucination—Vincristine—muscle cancer	0.00152	0.00687	CcSEcCtD
Ceftazidime—Vaginal inflammation—Methotrexate—muscle cancer	0.00148	0.00667	CcSEcCtD
Ceftazidime—Pancytopenia—Etoposide—muscle cancer	0.00147	0.00664	CcSEcCtD
Ceftazidime—Neutropenia—Etoposide—muscle cancer	0.00145	0.00654	CcSEcCtD
Ceftazidime—Skin exfoliation—Methotrexate—muscle cancer	0.00141	0.00637	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.00141	0.00636	CcSEcCtD
Ceftazidime—Vaginal infection—Methotrexate—muscle cancer	0.0014	0.0063	CcSEcCtD
Ceftazidime—Angiopathy—Vincristine—muscle cancer	0.00139	0.00627	CcSEcCtD
Ceftazidime—Aplastic anaemia—Methotrexate—muscle cancer	0.00139	0.00627	CcSEcCtD
Ceftazidime—Infestation NOS—Etoposide—muscle cancer	0.00138	0.00623	CcSEcCtD
Ceftazidime—Infestation—Etoposide—muscle cancer	0.00138	0.00623	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00137	0.00618	CcSEcCtD
Ceftazidime—Renal failure—Etoposide—muscle cancer	0.00136	0.00613	CcSEcCtD
Ceftazidime—Coma—Methotrexate—muscle cancer	0.00135	0.0061	CcSEcCtD
Ceftazidime—Jaundice—Etoposide—muscle cancer	0.00135	0.00608	CcSEcCtD
Ceftazidime—Leukopenia—Dactinomycin—muscle cancer	0.00134	0.00602	CcSEcCtD
Ceftazidime—Inflammation—Doxorubicin—muscle cancer	0.00132	0.00596	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Etoposide—muscle cancer	0.00131	0.0059	CcSEcCtD
Ceftazidime—Agranulocytosis—Etoposide—muscle cancer	0.00129	0.00582	CcSEcCtD
Ceftazidime—Vaginal inflammation—Doxorubicin—muscle cancer	0.00128	0.00578	CcSEcCtD
Ceftazidime—Thrombophlebitis—Methotrexate—muscle cancer	0.00124	0.0056	CcSEcCtD
Ceftazidime—Colitis—Doxorubicin—muscle cancer	0.00123	0.00555	CcSEcCtD
Ceftazidime—Agitation—Vincristine—muscle cancer	0.00123	0.00553	CcSEcCtD
Ceftazidime—Candida infection—Doxorubicin—muscle cancer	0.00122	0.00552	CcSEcCtD
Ceftazidime—Skin exfoliation—Doxorubicin—muscle cancer	0.00122	0.00552	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—muscle cancer	0.00121	0.00546	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—muscle cancer	0.0012	0.00543	CcSEcCtD
Ceftazidime—Leukopenia—Vincristine—muscle cancer	0.00119	0.00538	CcSEcCtD
Ceftazidime—Thrombocytopenia—Dactinomycin—muscle cancer	0.00119	0.00538	CcSEcCtD
Ceftazidime—Erythema multiforme—Etoposide—muscle cancer	0.00117	0.00529	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—muscle cancer	0.00117	0.00528	CcSEcCtD
Ceftazidime—Convulsion—Vincristine—muscle cancer	0.00116	0.00521	CcSEcCtD
Ceftazidime—Flushing—Etoposide—muscle cancer	0.00115	0.00519	CcSEcCtD
Ceftazidime—Angiopathy—Etoposide—muscle cancer	0.00113	0.00508	CcSEcCtD
Ceftazidime—Immune system disorder—Etoposide—muscle cancer	0.00112	0.00505	CcSEcCtD
Ceftazidime—Lethargy—Methotrexate—muscle cancer	0.0011	0.00494	CcSEcCtD
Ceftazidime—Anaphylactic shock—Vincristine—muscle cancer	0.00109	0.00491	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—muscle cancer	0.00108	0.00487	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—muscle cancer	0.00107	0.00485	CcSEcCtD
Ceftazidime—Nervous system disorder—Vincristine—muscle cancer	0.00107	0.00481	CcSEcCtD
Ceftazidime—Thrombocytopenia—Vincristine—muscle cancer	0.00107	0.00481	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—muscle cancer	0.00106	0.0048	CcSEcCtD
Ceftazidime—Dysgeusia—Etoposide—muscle cancer	0.00106	0.00477	CcSEcCtD
Ceftazidime—Pain—Dactinomycin—muscle cancer	0.00104	0.0047	CcSEcCtD
Ceftazidime—Hypotension—Vincristine—muscle cancer	0.00102	0.00459	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000996	0.00449	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—muscle cancer	0.000994	0.00448	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—muscle cancer	0.000986	0.00445	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—muscle cancer	0.000977	0.00441	CcSEcCtD
Ceftazidime—Paraesthesia—Vincristine—muscle cancer	0.000977	0.00441	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000967	0.00436	CcSEcCtD
Ceftazidime—Leukopenia—Etoposide—muscle cancer	0.000967	0.00436	CcSEcCtD
Ceftazidime—Abdominal pain—Dactinomycin—muscle cancer	0.000963	0.00434	CcSEcCtD
Ceftazidime—Body temperature increased—Dactinomycin—muscle cancer	0.000963	0.00434	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—muscle cancer	0.000949	0.00428	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Vincristine—muscle cancer	0.000939	0.00424	CcSEcCtD
Ceftazidime—Convulsion—Etoposide—muscle cancer	0.000936	0.00422	CcSEcCtD
Ceftazidime—Pain—Vincristine—muscle cancer	0.00093	0.0042	CcSEcCtD
Ceftazidime—Eosinophilia—Methotrexate—muscle cancer	0.000919	0.00415	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000913	0.00412	CcSEcCtD
Ceftazidime—Hypersensitivity—Dactinomycin—muscle cancer	0.000897	0.00405	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Vincristine—muscle cancer	0.00089	0.00401	CcSEcCtD
Ceftazidime—Pancytopenia—Methotrexate—muscle cancer	0.000882	0.00398	CcSEcCtD
Ceftazidime—Anaphylactic shock—Etoposide—muscle cancer	0.000881	0.00398	CcSEcCtD
Ceftazidime—Neutropenia—Methotrexate—muscle cancer	0.000868	0.00392	CcSEcCtD
Ceftazidime—Thrombocytopenia—Etoposide—muscle cancer	0.000863	0.00389	CcSEcCtD
Ceftazidime—Abdominal pain—Vincristine—muscle cancer	0.00086	0.00388	CcSEcCtD
Ceftazidime—Body temperature increased—Vincristine—muscle cancer	0.00086	0.00388	CcSEcCtD
Ceftazidime—Skin disorder—Etoposide—muscle cancer	0.000856	0.00386	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000838	0.00378	CcSEcCtD
Ceftazidime—Diarrhoea—Dactinomycin—muscle cancer	0.000833	0.00376	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—muscle cancer	0.000828	0.00373	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—muscle cancer	0.000828	0.00373	CcSEcCtD
Ceftazidime—Hypotension—Etoposide—muscle cancer	0.000824	0.00371	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000821	0.0037	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—muscle cancer	0.000814	0.00367	CcSEcCtD
Ceftazidime—Hypersensitivity—Vincristine—muscle cancer	0.000802	0.00362	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—muscle cancer	0.000796	0.00359	CcSEcCtD
Ceftazidime—Paraesthesia—Etoposide—muscle cancer	0.000791	0.00357	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—muscle cancer	0.000783	0.00353	CcSEcCtD
Ceftazidime—Vomiting—Dactinomycin—muscle cancer	0.000774	0.00349	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—muscle cancer	0.000773	0.00348	CcSEcCtD
Ceftazidime—Rash—Dactinomycin—muscle cancer	0.000768	0.00346	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—muscle cancer	0.000763	0.00344	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Etoposide—muscle cancer	0.000761	0.00343	CcSEcCtD
Ceftazidime—Pain—Etoposide—muscle cancer	0.000754	0.0034	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—muscle cancer	0.000752	0.00339	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—muscle cancer	0.000747	0.00337	CcSEcCtD
Ceftazidime—Diarrhoea—Vincristine—muscle cancer	0.000744	0.00336	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—muscle cancer	0.000743	0.00335	CcSEcCtD
Ceftazidime—Nausea—Dactinomycin—muscle cancer	0.000723	0.00326	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Etoposide—muscle cancer	0.000721	0.00325	CcSEcCtD
Ceftazidime—Dizziness—Vincristine—muscle cancer	0.00072	0.00325	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—muscle cancer	0.000717	0.00323	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—muscle cancer	0.000717	0.00323	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000711	0.00321	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—muscle cancer	0.000705	0.00318	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—muscle cancer	0.000703	0.00317	CcSEcCtD
Ceftazidime—Urticaria—Etoposide—muscle cancer	0.0007	0.00316	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—muscle cancer	0.000699	0.00315	CcSEcCtD
Ceftazidime—Body temperature increased—Etoposide—muscle cancer	0.000697	0.00314	CcSEcCtD
Ceftazidime—Abdominal pain—Etoposide—muscle cancer	0.000697	0.00314	CcSEcCtD
Ceftazidime—Vomiting—Vincristine—muscle cancer	0.000692	0.00312	CcSEcCtD
Ceftazidime—Rash—Vincristine—muscle cancer	0.000686	0.00309	CcSEcCtD
Ceftazidime—Dermatitis—Vincristine—muscle cancer	0.000685	0.00309	CcSEcCtD
Ceftazidime—Headache—Vincristine—muscle cancer	0.000682	0.00307	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000678	0.00306	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—muscle cancer	0.000674	0.00304	CcSEcCtD
Ceftazidime—Immune system disorder—Methotrexate—muscle cancer	0.000671	0.00303	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—muscle cancer	0.000669	0.00302	CcSEcCtD
Ceftazidime—Hypersensitivity—Etoposide—muscle cancer	0.000649	0.00293	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—muscle cancer	0.000647	0.00292	CcSEcCtD
Ceftazidime—Nausea—Vincristine—muscle cancer	0.000646	0.00292	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—muscle cancer	0.000643	0.0029	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—muscle cancer	0.000634	0.00286	CcSEcCtD
Ceftazidime—Pruritus—Etoposide—muscle cancer	0.000624	0.00281	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—muscle cancer	0.00061	0.00275	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—muscle cancer	0.000608	0.00274	CcSEcCtD
Ceftazidime—Diarrhoea—Etoposide—muscle cancer	0.000603	0.00272	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—muscle cancer	0.000597	0.00269	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—muscle cancer	0.000584	0.00263	CcSEcCtD
Ceftazidime—Dizziness—Etoposide—muscle cancer	0.000583	0.00263	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—muscle cancer	0.000581	0.00262	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—muscle cancer	0.000579	0.00261	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—muscle cancer	0.000561	0.00253	CcSEcCtD
Ceftazidime—Vomiting—Etoposide—muscle cancer	0.00056	0.00253	CcSEcCtD
Ceftazidime—Rash—Etoposide—muscle cancer	0.000556	0.00251	CcSEcCtD
Ceftazidime—Dermatitis—Etoposide—muscle cancer	0.000555	0.0025	CcSEcCtD
Ceftazidime—Headache—Etoposide—muscle cancer	0.000552	0.00249	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—muscle cancer	0.000549	0.00247	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000547	0.00247	CcSEcCtD
Ceftazidime—Anaphylactic shock—Methotrexate—muscle cancer	0.000528	0.00238	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—muscle cancer	0.000528	0.00238	CcSEcCtD
Ceftazidime—Nausea—Etoposide—muscle cancer	0.000524	0.00236	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—muscle cancer	0.000518	0.00234	CcSEcCtD
Ceftazidime—Thrombocytopenia—Methotrexate—muscle cancer	0.000517	0.00233	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—muscle cancer	0.000515	0.00232	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—muscle cancer	0.000513	0.00231	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—muscle cancer	0.000501	0.00226	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—muscle cancer	0.000493	0.00223	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—muscle cancer	0.000485	0.00219	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—muscle cancer	0.000474	0.00214	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000474	0.00214	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—muscle cancer	0.000457	0.00206	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000456	0.00206	CcSEcCtD
Ceftazidime—Pain—Methotrexate—muscle cancer	0.000451	0.00204	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—muscle cancer	0.000448	0.00202	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—muscle cancer	0.000448	0.00202	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—muscle cancer	0.000444	0.002	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—muscle cancer	0.000432	0.00195	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—muscle cancer	0.000427	0.00193	CcSEcCtD
Ceftazidime—Urticaria—Methotrexate—muscle cancer	0.000419	0.00189	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—muscle cancer	0.000417	0.00188	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—muscle cancer	0.000417	0.00188	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—muscle cancer	0.000411	0.00185	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000395	0.00178	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—muscle cancer	0.000391	0.00176	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—muscle cancer	0.000389	0.00175	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000374	0.00169	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—muscle cancer	0.000374	0.00168	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—muscle cancer	0.000363	0.00164	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—muscle cancer	0.000361	0.00163	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—muscle cancer	0.000361	0.00163	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—muscle cancer	0.000361	0.00163	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—muscle cancer	0.000349	0.00157	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—muscle cancer	0.000337	0.00152	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—muscle cancer	0.000336	0.00151	CcSEcCtD
Ceftazidime—Rash—Methotrexate—muscle cancer	0.000333	0.0015	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—muscle cancer	0.000333	0.0015	CcSEcCtD
Ceftazidime—Headache—Methotrexate—muscle cancer	0.000331	0.00149	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—muscle cancer	0.000323	0.00146	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—muscle cancer	0.000314	0.00141	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—muscle cancer	0.000313	0.00141	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—muscle cancer	0.000302	0.00136	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—muscle cancer	0.000291	0.00131	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—muscle cancer	0.000288	0.0013	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—muscle cancer	0.000288	0.0013	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—muscle cancer	0.000286	0.00129	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—muscle cancer	0.000272	0.00122	CcSEcCtD
